Shares of Anbio Biotechnology (NASDAQ:NNNN – Get Free Report) saw an uptick in trading volume on Monday . Approximately 76,536 shares traded hands during mid-day trading, an increase of 44% from the previous session’s volume of 53,183 shares.The stock last traded at $7.6220 and had previously closed at $6.81.
Analyst Ratings Changes
Separately, Weiss Ratings downgraded Anbio Biotechnology from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.
View Our Latest Analysis on NNNN
Anbio Biotechnology Stock Performance
About Anbio Biotechnology
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Read More
- Five stocks we like better than Anbio Biotechnology
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
- If Boeing Ramps Up Production, These Suppliers May Win Big
- Marvell Takes a Shot a Broadcom’s Throne With Google Deal
- 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here’s Why
Receive News & Ratings for Anbio Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anbio Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
